FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386665781> ?p ?o ?g. }

• W4386665781 abstract "Introduction: Limited data are available on safety and efficacy of second-generation cryoballoon (CB2) for cryoablation of atrial fibrillation (CBA). Hypothesis: To evaluate in a large cohort of patients treated in real world clinical settings, demographics, procedural data and outcomes comparing CB2 to first-generation cryoballoon (CB1). Methods: Between 2012 and 2014, 581 patients (74% men, 59±10 years, 78% paroxysmal AF, LA diameter: 41±6 mm) suffering from AF and undergoing pulmonary veins (PV) CBA were prospectively enrolled in ClinicalService® framework One Shot TO Pulmonary vein isolation (1STOP) project. The cohort was divided into 2 groups according to the cryoballoon used in standard clinical practice: 120 (21%) CB1 and 461 (79%) CB2. Results: Clinical and demographic characteristics were similar in the two cohorts; procedure, fluoroscopy and ablation time were significantly lower in CB2 respect to CB1 (141±40 vs 166±50 min, p<.001; 35±15 vs 41±15 min, p<.001; 27±17 vs 41±26 min, p<.001) with comparable acute success rate (97.8 vs 97.4%, p=ns); 22 patients (3.8%) experienced procedural complications. The most frequent acute procedural complication was transient diaphragmatic paralysis, significantly lower in CB2 vs CB1 (0.7 vs 3.3%, p=.016). Data at a minimum FU of 6 months were available for 237 (41%) patients: annual rate of follow-up complications was significantly lower in CB2 vs CB1 (Rate*100 pt/years: 5.74 vs 17.92, Incidence Rate Ratio - IRR: 0.32; 95% CI 0.17- 0.60; p<.001) as well as CB2 was associated with lower PV reconnection rate causing redo ablation (Rate*100 pt/years: 0.64 vs 4.98; IRR: 0.13; 95% CI 0.05-0.30; p<.001); 25 complications in 16 patients have been reported during FU, 21 (84%) of which for AF recurrence. Kaplain Meier analysis showed that freedom from AF at 12 months for patients with paroxysmal indication, considering a blanking period of 3 months, was 67.8% (95% CI 53.1-78.8%) in CB1 group and 77.8% (95% CI 68.6-84.7%) in CB2. Conclusions: The novel cryoballoon Arctic Front Advance (CB2) has proven to achieve, in a large clinical standard setting, significantly faster CBA times in comparison with the first-generation balloon, results also in lower acute procedural complication rates and a 78% 1-year freedom from AF." @default.
• W4386665781 created "2023-09-13" @default.
• W4386665781 creator A5000007680 @default.
• W4386665781 creator A5001848069 @default.
• W4386665781 creator A5007042709 @default.
• W4386665781 creator A5009909916 @default.
• W4386665781 creator A5021539954 @default.
• W4386665781 creator A5033337882 @default.
• W4386665781 creator A5043515003 @default.
• W4386665781 creator A5051346252 @default.
• W4386665781 creator A5055447547 @default.
• W4386665781 creator A5059963330 @default.
• W4386665781 creator A5080377110 @default.
• W4386665781 date "2015-11-10" @default.
• W4386665781 modified "2023-10-11" @default.
• W4386665781 title "Abstract 13991: Acute Procedural and Clinical Outcome Comparison Using the First and Second-Generation Cryoballoon: Inside a Large Cohort of Data Derived From Real World Multicentric Experience" @default.
• W4386665781 doi "https://doi.org/10.1161/circ.132.suppl_3.13991" @default.
• W4386665781 hasPublicationYear "2015" @default.
• W4386665781 type Work @default.
• W4386665781 citedByCount "0" @default.
• W4386665781 crossrefType "journal-article" @default.
• W4386665781 hasAuthorship W4386665781A5000007680 @default.
• W4386665781 hasAuthorship W4386665781A5001848069 @default.
• W4386665781 hasAuthorship W4386665781A5007042709 @default.
• W4386665781 hasAuthorship W4386665781A5009909916 @default.
• W4386665781 hasAuthorship W4386665781A5021539954 @default.
• W4386665781 hasAuthorship W4386665781A5033337882 @default.
• W4386665781 hasAuthorship W4386665781A5043515003 @default.
• W4386665781 hasAuthorship W4386665781A5051346252 @default.
• W4386665781 hasAuthorship W4386665781A5055447547 @default.
• W4386665781 hasAuthorship W4386665781A5059963330 @default.
• W4386665781 hasAuthorship W4386665781A5080377110 @default.
• W4386665781 hasConcept C126322002 @default.
• W4386665781 hasConcept C141071460 @default.
• W4386665781 hasConcept C2777628079 @default.
• W4386665781 hasConcept C2778902805 @default.
• W4386665781 hasConcept C2779161974 @default.
• W4386665781 hasConcept C42219234 @default.
• W4386665781 hasConcept C71924100 @default.
• W4386665781 hasConcept C72563966 @default.
• W4386665781 hasConceptScore W4386665781C126322002 @default.
• W4386665781 hasConceptScore W4386665781C141071460 @default.
• W4386665781 hasConceptScore W4386665781C2777628079 @default.
• W4386665781 hasConceptScore W4386665781C2778902805 @default.
• W4386665781 hasConceptScore W4386665781C2779161974 @default.
• W4386665781 hasConceptScore W4386665781C42219234 @default.
• W4386665781 hasConceptScore W4386665781C71924100 @default.
• W4386665781 hasConceptScore W4386665781C72563966 @default.
• W4386665781 hasIssue "suppl_3" @default.
• W4386665781 hasLocation W43866657811 @default.
• W4386665781 hasOpenAccess W4386665781 @default.
• W4386665781 hasPrimaryLocation W43866657811 @default.
• W4386665781 hasRelatedWork W1967841144 @default.
• W4386665781 hasRelatedWork W2018480046 @default.
• W4386665781 hasRelatedWork W2064495796 @default.
• W4386665781 hasRelatedWork W2100553915 @default.
• W4386665781 hasRelatedWork W2319489406 @default.
• W4386665781 hasRelatedWork W2603808924 @default.
• W4386665781 hasRelatedWork W2763816051 @default.
• W4386665781 hasRelatedWork W2916136282 @default.
• W4386665781 hasRelatedWork W3034632274 @default.
• W4386665781 hasRelatedWork W4244544265 @default.
• W4386665781 hasVolume "132" @default.
• W4386665781 isParatext "false" @default.
• W4386665781 isRetracted "false" @default.
• W4386665781 workType "article" @default.